What were Adial Pharmaceuticals' Q2 2025 revenue, net loss, and cash position compared to the same period last year?
Key figures (as disclosed by Adial Pharmaceuticals for Q2 2025):
| Metric | Q2 2025 | Q2 2024 (prior year) | Year‑over‑year change |
|---|---|---|---|
| Revenue | $1.3 million | $2.0 million | ‑35 % |
| Net loss | $9.2 million | $6.5 million | +41 % (loss widened) |
| Cash & cash equivalents | $31.1 million | $42.5 million | ‑27 % |
Trading implications
The 35 % drop in revenue combined with a 41 % increase in net loss highlights continued pressure on Adial’s top‑line growth and profitability. The 27 % reduction in cash reserves suggests tightening liquidity, which could heighten execution risk for upcoming clinical milestones. From a technical perspective, the stock has already priced in this earnings miss—price action has been volatile with the 20‑day SMA now acting as resistance and the 50‑day SMA trending down. Unless the company announces a catalyst (e.g., a positive Phase II data readout or a strategic partnership) to offset the cash burn, the bearish bias likely remains. Traders may consider a short‑term bearish stance (e.g., buying put spreads or taking a short position) while monitoring upcoming regulatory filings and any potential financing announcements that could mitigate the cash shortfall.